Rain Therapeutics Inc. is a clinical-stage company in the United States that develops therapies targeting oncogenic drivers, with a lead product candidate being milademetan, a small molecule oral inhibitor of mouse double minute 2. Milademetan is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma. The company is also developing RAD52, which is in preclinical trials for various tumors, including breast, ovarian, pancreatic, prostate, and other cancers.